Ageing and Cancer Research & Treatment

  • Ageing and Cancer Research & Treatment (ACRT, Print ISSN 2972-4759 Online ISSN 2972-4767) is a peer-reviewed, open-access journal published online and owned by Science Exploration Press. The journal is dedicated to the promulgation of research addressing how ageing affects carcinogenesis and host-tumor interactions in humans and experimental models. Basic, translational and clinical cancer research from genes to molecules to tissues and organs in the context of ageing will be considered. The journal welcomes Research Articles, Reviews, Meta-Analyses, Commentaries, Perspectives, Technical Notes, Editorials, Opinions, etc. more >
  • Ageing and Cancer Research & Treatment (ACRT, Print ISSN 2972-4759 Online ISSN 2972-4767) is a peer-reviewed, open-access journal published online and owned by Science Exploration Press. The journal is dedicated to the promulgation of research addressing how ageing affects carcinogenesis and host-tumor interactions in humans and experimental models. Basic, translational and clinical cancer research from genes to molecules to tissues and organs in the context of ageing will be considered. The journal welcomes Research Articles, Reviews, Meta-Analyses, Commentaries, Perspectives, Technical Notes, Editorials, Opinions, etc. more >
Does ageing modulate interactions between mesothelioma cells, macrophages, and tumour endothelial cells?
  • It is becoming increasingly clear that the tumour microenvironment (TME) adopts a changing and increasingly complex landscape as tumours evolve. Central to the TME, and alongside malignant cells, are tissue resident and recruited macrophages, other immune ... More

  • Lelinh Duong, ... Delia J Nelson
Download PDF View: Download:
Ribociclib plus letrozole alters the blood immune profile in older patients with HR+/HER2- metastatic breast cancer
  • Aims: The combination of CDK4/6 inhibitors and endocrine therapy (ET) is a standard first-line therapy for hormone receptor positive (HR+)/HER2- metastatic breast cancer (mBC). Preliminary data suggest that CDK4/6 inhibitors can alter the host ... More

  • Yentl Lambrechts, ... Hans Wildiers
Download PDF View: Download:
Immunotherapy: should we worry about immunosenescence?
  • The global aging population is expected to experience a nofigure increase in cancer incidence, particularly among individuals aged 70 and older. At the same time, the extensive use of immune checkpoint inhibitors (ICIs) in cancer treatment raises questions ... More

  • Asli Özkan, ... Johanneke E. A. Portielje
Download PDF View: Download:
Treatment with the thymic polypeptide fraction Biomodulina T potentiates immune responses in older adults and cancer patients: an overview of the most recent studies
  • Over the past 50 years, the world has experienced a progressive demographic shift resulting in a higher proportion of older adults in the general population. Aging itself is a complex biological phenomenon, characterized in part by changes in the immune system, ... More

  • Danay Saavedra, ... Agustín Lage
Download PDF View: Download:
Ageing and its role in modulating healthy and tumour-associated macrophages
  • Western and third world countries alike are experiencing population ageing with people living longer. The World Health Organization website states that ‘between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from ... More

  • Lelinh Duong, ... Delia J Nelson
Download PDF View: Download:
Ribociclib plus letrozole alters the blood immune profile in older patients with HR+/HER2- metastatic breast cancer
  • Aims: The combination of CDK4/6 inhibitors and endocrine therapy (ET) is a standard first-line therapy for hormone receptor positive (HR+)/HER2- metastatic breast cancer (mBC). Preliminary data suggest that CDK4/6 inhibitors can alter the host ... More

  • Yentl Lambrechts, ... Hans Wildiers
Download PDF View: Download:
Does ageing modulate interactions between mesothelioma cells, macrophages, and tumour endothelial cells?
  • It is becoming increasingly clear that the tumour microenvironment (TME) adopts a changing and increasingly complex landscape as tumours evolve. Central to the TME, and alongside malignant cells, are tissue resident and recruited macrophages, other immune ... More

  • Lelinh Duong, ... Delia J Nelson
Download PDF View: Download:
Immunotherapy: should we worry about immunosenescence?
  • The global aging population is expected to experience a nofigure increase in cancer incidence, particularly among individuals aged 70 and older. At the same time, the extensive use of immune checkpoint inhibitors (ICIs) in cancer treatment raises questions ... More

  • Asli Özkan, ... Johanneke E. A. Portielje
Download PDF View: Download:
Elderly lung cancer patients show tumor-infiltrating CD8+ T Cell responses enriched with PDCD1 and CXCL13 after neoadjuvant therapy with Anti-PD-1
  • Aims: Aged individuals are significantly underrepresented in immunotherapy clinical trials for cancer. Little is known regarding the immunological and molecular dynamics that might regulate their responsiveness to immune checkpoint inhibitors ... More

  • Fernanda Tereza Bovi Frozza, ... Cristina Bonorino
Download PDF View: Download:
Ageing and Cancer Research & Treatment
  • Increasing life expectancy globally results in predictions that one in six people will be > 65 years of age by 2050. Because the occurrence of most cancers is strongly associated with older age, a significant increase in the number of older adults with cancer is ... More

  • Bueno Valquiria, Pawelec Graham
Download PDF View: Download:
Ribociclib plus letrozole alters the blood immune profile in older patients with HR+/HER2- metastatic breast cancer
  • Aims: The combination of CDK4/6 inhibitors and endocrine therapy (ET) is a standard first-line therapy for hormone receptor positive (HR+)/HER2- metastatic breast cancer (mBC). Preliminary data suggest that CDK4/6 inhibitors can alter the host ... More

  • Yentl Lambrechts, ... Hans Wildiers
Download PDF View: Download:
Elderly lung cancer patients show tumor-infiltrating CD8+ T Cell responses enriched with PDCD1 and CXCL13 after neoadjuvant therapy with Anti-PD-1
  • Aims: Aged individuals are significantly underrepresented in immunotherapy clinical trials for cancer. Little is known regarding the immunological and molecular dynamics that might regulate their responsiveness to immune checkpoint inhibitors ... More

  • Fernanda Tereza Bovi Frozza, ... Cristina Bonorino
Download PDF View: Download:
Immunotherapy: should we worry about immunosenescence?
  • The global aging population is expected to experience a nofigure increase in cancer incidence, particularly among individuals aged 70 and older. At the same time, the extensive use of immune checkpoint inhibitors (ICIs) in cancer treatment raises questions ... More

  • Asli Özkan, ... Johanneke E. A. Portielje
Download PDF View: Download:
Does ageing modulate interactions between mesothelioma cells, macrophages, and tumour endothelial cells?
  • It is becoming increasingly clear that the tumour microenvironment (TME) adopts a changing and increasingly complex landscape as tumours evolve. Central to the TME, and alongside malignant cells, are tissue resident and recruited macrophages, other immune ... More

  • Lelinh Duong, ... Delia J Nelson
Download PDF View: Download:
Is less always more? Emerging treatment concepts in geriatric hemato-oncology
  • The outcomes of older adults with cancer are still dismal despite some progress within the last years. This is mainly due to comorbidities, overall frailty, and differences in disease biology. The better understanding of tumor biology and immunology has enabled ... More

  • Nina Rosa Neuendorff, ... Konstantinos Christofyllakis
Download PDF View: Download:

Special Issues

  • Submission Deadline: 15 Sep 2025
  • Published articles: 0
Telomeres in Aging and Cancer
Prof. Gabriele Saretzki
  • Submission Deadline: 15 Sep 2025
  • Published articles: 0
Ageing and Immunotherapy in Cancer
Dr. Constantin N. Baxevanis, Dr. Maria Goulielmaki
  • Submission Deadline: 30 Jun 2025
  • Published articles: 0
Editor-in-Chief
Volumes
News